Revolutionizing Parasitic Disease Treatment: Prof. Li Jun’s Nanodrug Breakthrough for Liver-Targeted Therapy

A promising innovation is emerging in the fight against hepatic alveolar echinococcosis (AE) — a lethal parasitic disease that predominantly attacks the liver. At the International Congress on Materials Science and Nanotechnology 2025, Prof. Li Jun from The First Affiliated Hospital of Xinjiang Medical University, China, will present her pioneering research on oral nanodrug delivery systems designed to overcome the limitations of current AE therapies.

🎯 Title: Oral delivery of liver-targeting nanodrug against hepatic alveolar echinococcosis

---

💡 About the Research

AE remains one of the world’s most neglected tropical diseases, often leading to fatal liver complications due to ineffective drug delivery. Prof. Li Jun’s study introduces a nanoparticle-based oral drug formulation that can precisely target liver tissue while reducing systemic toxicity.

Using biocompatible PLGA nanoparticles, her team encapsulated a novel carbazole aminoalcohol compound (H1402) — a potent anti-AE agent identified in earlier research. This formulation, termed H1402-NPs, demonstrated remarkable potential in both laboratory and animal models.

---

⚗️ Key Highlights from the Study

·         🧪 Efficient Drug Encapsulation: The nanoparticles achieved 82.1% encapsulation efficiency and 8.2% drug loading, forming uniform spherical particles averaging 55 nm.

·         ⚙️ Enhanced Targeting Ability: H1402-NPs rapidly penetrated the parasite’s vesicle wall and accumulated within one hour inside Echinococcus multilocularis vesicles.

·         💊 Improved Liver Distribution: Imaging studies revealed significantly higher liver accumulation compared to unencapsulated H1402, ensuring better drug action at the infection site.

·         🧫 Superior Treatment Outcomes: After 30 days of oral administration (100 mg/kg/day) in a murine model, the nanodrug reduced:

o    📉 Parasite mass by 8.8%

o    📏 Vesicle size by 89.9%

·         🧬 Reduced Toxicity: H1402-NPs displayed minimal hepatotoxicity and cytotoxicity, outperforming both albendazole and free H1402 treatments.

·         🌟 Therapeutic Promise: These findings highlight the potential of H1402-NPs as a liver-targeted nanodrug capable of addressing current barriers in AE therapy.

---

👩‍🔬 About Prof. Li Jun

Prof. Li Jun is a distinguished researcher at the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, China.
She earned her Ph.D. from the University of Queensland, Australia, where she developed diagnostic tools for parasitic infections.
With over 80 publications in leading scientific journals, her research focuses on molecular parasitology, nanomedicine, and infectious disease therapeutics.

---

🌐 Conference Details

📅 Dates: November 20–22, 2025
📍 Venue: Singapore & Online (Hybrid Event)
🎓 Event: International Congress on Materials Science and Nanotechnology
🔗 Website: https://materials.miconferences.com/
📝 Register: https://materials.miconferences.com/register
📬 Submit Abstract: https://materials.miconferences.com/abstract-submission
📧 Email: materials@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967
🐦 Follow us: @MNanoConference

---

#MaterialsScience2025 #Nanotechnology #LiverTargetedDrug #BiomedicalInnovation #Nanomedicine #DrugDeliverySystems #PLGANanoparticles #EchinococcosisResearch #ParasiticDiseases #HepaticTherapy #XinjiangMedicalUniversity #PharmaceuticalScience #ScientificBreakthrough #ResearchInnovation #SingaporeEvent #MNanoConference #FutureOfMedicine